Effective natural food complements: anti-CoV-2 spike protein directed druggable inhibitors

Abstract

There is a number of photosynthetically produced small molecules that have previously been validated through SARS-CoV spike protein interaction assays for selectivity and effectivity in our database. Our specialty database, the AVIRA-DB, has been built from scientific papers that published results regarding selective & effective CoV-2 spike protein binding inhibitors that prevent virus binding to the Angiotensin Converting Enzyme type 2 (ACE2). These data have been accumulated since 2003, the time of the first well documented coronavirus pandemic. To develop our anti-viral nutraceutical capsule we favoured small molecules (Mw <1000 Dalton) from edible plant parts that are enriched in experimentally evaluated coronavirus inhibitors. From this “AVIRA-DB” we screened for local culture varieties of vegetables and spices that are enriched in the anti-viral hits. Thus, AVIRA is the first knowledge-based nutraceutical composition that was validated by selective anti-CoV-2’s spike protein assays, performed in silico, -vitro & -vivo. From Chemo- & Bio-text-mined meta-data from literature and patents resulted in druggable flavonoids and flavonols, which were validated as anti-CoV-2 spike protein directed small molecules that are preventing the binding of the virus to ACE2.